Apellis Pharmaceuticals to Host Conference Call on November 5, 2024, to Discuss Third Quarter 2024 Financial Results
Apellis Pharmaceuticals (Nasdaq: APLS) has announced it will host a conference call and webcast on November 5, 2024, at 8:30 a.m. ET to discuss its third quarter 2024 financial results. Interested parties can pre-register for the call, and a live audio webcast with accompanying slides will be accessible through the company's website. A replay of the webcast will be available for 90 days following the event.
Apellis is a global biopharmaceutical company focused on developing life-changing therapies for challenging diseases. They have introduced the first new class of complement medicine in 15 years and currently have two approved medicines targeting C3, including the first-ever therapy for geographic atrophy, a leading cause of blindness worldwide. The company aims to further explore the potential of targeting C3 across various retinal, rare, and neurological diseases.
Apellis Pharmaceuticals (Nasdaq: APLS) ha annunciato che ospiterà una conference call e un webcast il 5 novembre 2024, alle 8:30 ET per discutere i suoi risultati finanziari del terzo trimestre 2024. Le parti interessate possono registrarsi in anticipo per la chiamata, e sarà disponibile un webcast audio live con diapositive sul sito web della compagnia. Una registrazione del webcast sarà disponibile per 90 giorni dopo l'evento.
Apellis è un'azienda biofarmaceutica globale che si concentra sullo sviluppo di terapie in grado di cambiare la vita per malattie difficili. Hanno introdotto la prima nuova classe di medicina complementare dopo 15 anni e attualmente hanno due medicinali approvati che mirano a C3, compresa la prima terapia mai approvata per l'atrofia geografica, una delle principali cause di cecità a livello mondiale. L'azienda mira a esplorare ulteriormente il potenziale del targeting di C3 in diverse malattie retiniche, rare e neurologiche.
Apellis Pharmaceuticals (Nasdaq: APLS) ha anunciado que celebrará una conferencia telefónica y un webcast el 5 de noviembre de 2024, a las 8:30 a.m. ET para discutir sus resultados financieros del tercer trimestre de 2024. Las partes interesadas pueden pre-registrarse para la llamada, y un webcast de audio en vivo con diapositivas estará disponible a través del sitio web de la compañía. Una repetición del webcast estará disponible durante 90 días después del evento.
Apellis es una empresa biofarmacéutica global centrada en desarrollar terapias que cambian la vida para enfermedades desafiantes. Han introducido la primera nueva clase de medicina complementaria en 15 años y actualmente tienen dos medicamentos aprobados que apuntan a C3, incluida la primera terapia para la atrofia geográfica, una de las principales causas de ceguera en todo el mundo. La compañía busca explorar más a fondo el potencial de apuntar a C3 en diversas enfermedades retinianas, raras y neurológicas.
Apellis Pharmaceuticals (Nasdaq: APLS)는 2024년 11월 5일, 오전 8시 30분 ET에 컨퍼런스 콜과 웹캐스트를 개최하여 2024년 3분기 재무 결과를 논의할 것이라고 발표했습니다. 관심 있는 측은 전화에 사전 등록할 수 있으며, 회사 웹사이트를 통해 슬라이드와 함께 라이브 오디오 웹캐스트를 이용할 수 있습니다. 이벤트 이후 90일 동안 웹캐스트의 재생이 가능합니다.
Apellis는 도전적인 질병에 대한 삶을 변화시키는 치료제를 개발하는 데 중점을 둔 글로벌 생명공학 회사입니다. 그들은 15년 만에 첫 번째 새로운 클래스의 보완 의약품을 도입했으며 현재 C3를 표적으로 하는 두 가지 승인된 의약품을 보유하고 있으며, 이는 세계적으로 실명 주요 원인인 지리적 위축에 대한 최초의 치료법입니다. 이 회사는 다양한 망막, 희귀 및 신경 질환에 대해 C3를 겨냥하는 잠재력을 더욱 탐색할 계획입니다.
Apellis Pharmaceuticals (Nasdaq: APLS) a annoncé qu'il tiendrait une conférence téléphonique et un webinaire le 5 novembre 2024 à 8h30 ET pour discuter de ses résultats financiers du troisième trimestre 2024. Les parties intéressées peuvent s'inscrire à l'avance pour l'appel, et un webinaire audio en direct avec des diapositives sera accessible via le site internet de l'entreprise. Une rediffusion du webinaire sera disponible pendant 90 jours après l'événement.
Apellis est une entreprise biopharmaceutique mondiale axée sur le développement de thérapies capables de changer des vies pour des maladies difficiles. Ils ont introduit la première nouvelle classe de médicaments complémentaires en 15 ans et disposent actuellement de deux médicaments approuvés ciblant le C3, dont la première thérapie pour l'atrophie géographique, une des principales causes de cécité dans le monde. L'entreprise vise à explorer davantage le potentiel de cibler le C3 dans diverses maladies rétiniennes, rares et neurologiques.
Apellis Pharmaceuticals (Nasdaq: APLS) hat angekündigt, dass am 5. November 2024 um 8:30 Uhr ET eine Telefonkonferenz und ein Webcast stattfinden werden, um die Finanzergebnisse des dritten Quartals 2024 zu besprechen. Interessierte Parteien können sich im Voraus für den Anruf registrieren, und ein Live-Audio-Webcast mit begleitenden Folien wird über die Website des Unternehmens zugänglich sein. Eine Aufzeichnung des Webcasts wird 90 Tage nach der Veranstaltung verfügbar sein.
Apellis ist ein globales Biopharma-Unternehmen, das sich auf die Entwicklung lebensverändernder Therapien für herausfordernde Krankheiten spezialisiert hat. Sie haben die erste neue Klasse von Komplementmedizin seit 15 Jahren eingeführt und verfügen derzeit über zwei genehmigte Arzneimittel, die auf C3 abzielen, einschließlich der ersten Therapie gegen geografische Atrophie, einer der Hauptursachen für Erblindung weltweit. Das Unternehmen strebt an, das Potenzial der C3-Targetierung in verschiedenen retinalen, seltenen und neurologischen Erkrankungen weiter zu erkunden.
- Apellis has two approved medicines targeting C3
- Developed first-ever therapy for geographic atrophy, a leading cause of blindness
- None.
WALTHAM, Mass., Oct. 22, 2024 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (Nasdaq: APLS) today announced that the company will host a conference call and webcast to discuss its third quarter 2024 financial results on Tuesday, November 5, 2024, at 8:30 a.m. ET.
To access the live call by phone, please pre-register for the call here. A live audio webcast of the event and accompanying slides may also be accessed through the “Events and Presentations” page of the “Investors and Media” section of the company’s website. A replay of the webcast will be available for 90 days following the event.
About Apellis
Apellis Pharmaceuticals, Inc. is a global biopharmaceutical company that combines courageous science and compassion to develop life-changing therapies for some of the most challenging diseases patients face. We ushered in the first new class of complement medicine in 15 years and now have two approved medicines targeting C3. These include the first-ever therapy for geographic atrophy, a leading cause of blindness around the world. We believe we have only begun to unlock the potential of targeting C3 across serious retinal, rare, and neurological diseases. For more information, please visit http://apellis.com or follow us on Twitter and LinkedIn.
Investor Contact:
Meredith Kaya
meredith.kaya@apellis.com
617.599.8178
FAQ
When will Apellis Pharmaceuticals (APLS) report its Q3 2024 financial results?
How can investors access Apellis Pharmaceuticals' (APLS) Q3 2024 earnings call?
What are the key therapeutic areas Apellis Pharmaceuticals (APLS) is focusing on?
How long will the replay of Apellis Pharmaceuticals' (APLS) Q3 2024 earnings webcast be available?
